Home
About SinovacProductsPipelineInvestorsContact Us
 
 
  SITEMAP 中文版
         
 
 
SINOVAC OVERVIEW
Sinovac Biotech Ltd. (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. Sinovac is one of the leading emerging biotechnology companies in China.

Working closely with Chinese public health officials, Sinovac focuses on manufacturing and marketing human-use vaccines and related products, and currently markets its vaccine for Hepatitis A. Sinovac is the first and currently the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS.
 

 
LATEST NEWS More Info
  • Sinovac Schedules 2008 Annual General Meeting »
  • Sinovac Receives Revised Approvals for Panflu »
  • Sinovac Receives China's First Influenza A (H1N1) Vaccine Order »
  • Sinovac Begins the Production of Influenza A (H1N1) Vaccine »
  • China's Vice Premier, Li Keqiang, Visits Sinovac to Inspect H1N1 Vaccine Production Preparation »
  •  
     
     

     
    GET LATEST NEWS
    Enter your email below to receive up-to-date info:
    Your name
    Email
    Subscribe

    Copyright © 2009 Sinovac Biotech Ltd. All rights reserved.